Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.42 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004267 | 0.78 | LOXL2 (0.64) | LOXL2CYP2A6IDO1CYP19A1KCNJ1 | |
| SCHEMBL1344068 | 0.78 | LOXL2 (0.65) | LOXL2CYP2A6IDO1CYP19A1KCNJ1 | |
| Bromide SCHEMBL7210305 | 0.77 | LOXL2 (0.56) | LOXL2CYP2A6IDO1CYP19A1KCNJ1 | |
| Bromide SCHEMBL6436882 | 0.77 | LOXL2 (0.95) | LOXL2CYP2A6IDO1CYP19A1KCNJ1 | |
| Water SCHEMBL28189314 | 0.76 | CA2 (0.69) | LOXL2CYP2A6ALDH1A1CA12CA2 | |
| SCHEMBL2503454 | 0.76 | CA2 (0.69) | LOXL2CYP2A6ALDH1A1CA12CA2 | |
| Water SCHEMBL28254092 | 0.76 | CA2 (0.69) | LOXL2CYP2A6ALDH1A1CA12CA2 | |
| SCHEMBL45942 | 0.76 | CA2 (0.69) | LOXL2CYP2A6ALDH1A1CA12CA2 | |
| SCHEMBL23334089 | 0.74 | LOXL2 (0.58) | LOXL2CYP2A6IDO1CYP19A1KCNJ1 | |
| SCHEMBL200142 | 0.74 | LOXL2 (0.58) | LOXL2CYP2A6IDO1CYP19A1KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180165-B2 | Human TLR8-selective agonists | UNIVERSITY OF KANSAS (US) | 2024-12-31 | — | — | US | disclosed |
| WO-2024008909-A1 | INHIBITORS OF CORONAVIRUS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-11 | — | — | WO | disclosed |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2022-01-06 | — | — | US | disclosed |
| US-11130736-B2 | Human TLR8-selective agonists | UNIVERSITY OF KANSAS (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3337481-B1 | QUINOLINE-2-AMINE DERIVATIVES AS HUMAN TLR8-SELECTIVE AGONISTS FOR INCREASING IMMUNE RESPONSE | UNIV KANSAS (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20180258045-A1 | HUMAN TLR8-SELECTIVE AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-13 | — | — | US | disclosed |
| EP-3337481-A1 | HUMAN TLR8-SELECTIVE AGONISTS | The University of Kansas (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017034986-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016067143-A1 | N-(2-ALKYLENEIMINO-3-PHENYLPROPYL)ACETAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND PRURITUS VIA INHIBITION OF TRPA1 CHANNELS | PFIZER INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION | 2005-07-21 | — | — | US | disclosed |
| WO-2005051398-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005047258-A2 | METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION | WYETH (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101569-A1 | Methods and compositions for selectin inhibition | WYETH (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005033073-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004050018-A2 | DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130736-B2 | Human TLR8-selective agonists | TLR7, TLR8, TLR9 | LOXL2 2014/4885CYP2A6 3555/4885IDO1 1940/4885 |
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | NR0B1, NR2C2, DECR1 | LOXL2 692/4885CYP2A6 512/4885IDO1 1522/4885 |
| US-20050101569-A1 | Methods and compositions for selectin inhibition | SELP, SELE, SELL | LOXL2 782/4885CYP2A6 2377/4885IDO1 2597/4885 |
| US-20180258045-A1 | HUMAN TLR8-SELECTIVE AGONISTS | TLR7, TLR8, TLR9 | LOXL2 2014/4885CYP2A6 3555/4885IDO1 1940/4885 |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | LOXL2 1677/4885CYP2A6 137/4885IDO1 1463/4885 |
| US-12180165-B2 | Human TLR8-selective agonists | TLR7, TLR8, TLR9 | LOXL2 2014/4885CYP2A6 3555/4885IDO1 1940/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | LOXL2 3142/4885CYP2A6 268/4885IDO1 3762/4885 |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | TLR7, TLR8, TLR9 | LOXL2 2014/4885CYP2A6 3555/4885IDO1 1940/4885 |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | OPRK1, OPRD1, OPRL1 | LOXL2 1677/4885CYP2A6 137/4885IDO1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.